Device Trial Radar · NCT05868044
REsponse to Combined SONS and ONS in Chronic Cluster headachE
Last checked: Nov 19, 2026Latest source record: Apr 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
5
Planned (sponsor's estimate)
Start
May 2, 2023
Primary completion
Apr 23, 2024
Study completion Dec 30, 2026
Sponsor
- Lead sponsor
- Salvia BioElectronicsNot on our public-company list
- Sponsor type
- Industry
- First posted
- May 22, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Device feasibility
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to demonstrate the safe use of the PRIMUS System in subjects with chronic cluster headache. This is a single-centre, open label, prospective, first in human study to collect initial clinical data on the PRIMUS system for the treatment of chronic cluster headache.
Conditions
- Chronic Cluster Headache
Interventions
PRIMUSDevice
PRIMUS system
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety EvaluationTime frame: 4 weeks
- Safety EvaluationTime frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Resolve Pain
Buderim, Queensland, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.